Actinium Pharmaceuticals, Inc. (ATNM)
USD 1.16
(-4.92%)
USD 1.16
(-4.92%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.83 USD | -38.64% |
| 2022 | -1.32 USD | -10.0% |
| 2021 | -1.20 USD | 34.07% |
| 2020 | -1.82 USD | 58.35% |
| 2019 | -4.37 USD | 34.68% |
| 2018 | -6.69 USD | 44.06% |
| 2017 | -11.96 USD | 20.58% |
| 2016 | -15.06 USD | 8.89% |
| 2015 | -16.53 USD | 38.94% |
| 2014 | -27.07 USD | -90.5% |
| 2013 | -14.21 USD | 93.75% |
| 2012 | -227.31 USD | -59918.42% |
| 2011 | 0.38 USD | 8344.44% |
| 2010 | 0.00 USD | 107.49% |
| 2009 | -0.06 USD | 28.45% |
| 2008 | -0.08 USD | -111.06% |
| 2007 | -0.04 USD | 83.42% |
| 2006 | -0.24 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.38 USD | -22.58% |
| 2024 Q1 | -0.31 USD | 8.82% |
| 2023 FY | - USD | -38.64% |
| 2023 Q3 | -0.49 USD | 15.52% |
| 2023 Q2 | -0.58 USD | -41.46% |
| 2023 Q1 | -0.41 USD | -5.13% |
| 2023 Q4 | -0.34 USD | 30.61% |
| 2022 Q3 | -0.37 USD | -12.12% |
| 2022 FY | - USD | -10.0% |
| 2022 Q1 | -0.23 USD | 37.84% |
| 2022 Q2 | -0.33 USD | -43.48% |
| 2022 Q4 | -0.39 USD | -5.41% |
| 2021 Q2 | -0.25 USD | 13.79% |
| 2021 Q4 | -0.37 USD | -23.33% |
| 2021 FY | - USD | 34.07% |
| 2021 Q1 | -0.29 USD | 17.14% |
| 2021 Q3 | -0.30 USD | -20.0% |
| 2020 Q3 | -0.36 USD | 12.2% |
| 2020 FY | - USD | 58.35% |
| 2020 Q2 | -0.41 USD | 58.16% |
| 2020 Q1 | -0.98 USD | -16.67% |
| 2020 Q4 | -0.35 USD | 2.78% |
| 2019 Q1 | -1.45 USD | 12.12% |
| 2019 FY | - USD | 34.68% |
| 2019 Q2 | -1.00 USD | 31.03% |
| 2019 Q3 | -1.21 USD | -21.0% |
| 2019 Q4 | -0.84 USD | 30.58% |
| 2018 Q3 | -1.67 USD | -26.52% |
| 2018 FY | - USD | 44.06% |
| 2018 Q1 | -2.14 USD | -22.29% |
| 2018 Q2 | -1.32 USD | 38.32% |
| 2018 Q4 | -1.65 USD | 1.2% |
| 2017 FY | - USD | 20.58% |
| 2017 Q4 | -1.75 USD | 32.95% |
| 2017 Q3 | -2.61 USD | 28.3% |
| 2017 Q2 | -3.64 USD | 15.94% |
| 2017 Q1 | -4.33 USD | -19.61% |
| 2016 Q4 | -3.62 USD | 12.77% |
| 2016 Q2 | -4.28 USD | -43.14% |
| 2016 Q3 | -4.15 USD | 3.04% |
| 2016 Q1 | -2.99 USD | 32.51% |
| 2016 FY | - USD | 8.89% |
| 2015 FY | - USD | 38.94% |
| 2015 Q4 | -4.43 USD | -47.67% |
| 2015 Q3 | -3.00 USD | 50.9% |
| 2015 Q2 | -6.11 USD | -120.58% |
| 2015 Q1 | -2.77 USD | 43.35% |
| 2014 Q4 | -4.89 USD | 23.59% |
| 2014 FY | - USD | -90.5% |
| 2014 Q1 | -19.86 USD | -184.12% |
| 2014 Q2 | 4.20 USD | 121.15% |
| 2014 Q3 | -6.40 USD | -252.38% |
| 2013 Q1 | -0.97 USD | 91.71% |
| 2013 Q2 | -3.90 USD | -302.06% |
| 2013 Q3 | -1.81 USD | 53.59% |
| 2013 Q4 | -6.99 USD | -286.19% |
| 2013 FY | - USD | 93.75% |
| 2012 FY | - USD | -59918.42% |
| 2012 Q1 | -0.02 USD | -197.18% |
| 2012 Q3 | -112.72 USD | -3998.91% |
| 2012 Q4 | -11.70 USD | 89.62% |
| 2012 Q2 | -2.75 USD | -12933.18% |
| 2011 FY | - USD | 8344.44% |
| 2011 Q1 | -0.01 USD | 52.84% |
| 2011 Q2 | 0.06 USD | 609.26% |
| 2011 Q3 | -0.01 USD | -117.27% |
| 2011 Q4 | -0.01 USD | 25.26% |
| 2010 Q1 | -0.02 USD | 12.55% |
| 2010 Q4 | -0.02 USD | 11.92% |
| 2010 Q3 | -0.03 USD | -134.21% |
| 2010 FY | - USD | 107.49% |
| 2010 Q2 | 0.08 USD | 440.81% |
| 2009 Q3 | -0.01 USD | -5.05% |
| 2009 Q1 | -0.01 USD | 30.24% |
| 2009 FY | - USD | 28.45% |
| 2009 Q4 | -0.03 USD | -145.19% |
| 2009 Q2 | -0.01 USD | 30.77% |
| 2008 Q1 | -0.03 USD | -132.8% |
| 2008 Q2 | -0.03 USD | 12.37% |
| 2008 Q3 | -0.01 USD | 64.71% |
| 2008 Q4 | -0.02 USD | -127.78% |
| 2008 FY | - USD | -111.06% |
| 2007 Q3 | -0.02 USD | -87.91% |
| 2007 Q2 | -0.01 USD | -2175.0% |
| 2007 FY | - USD | 83.42% |
| 2007 Q1 | -0.00 USD | 98.22% |
| 2007 Q4 | -0.01 USD | 26.9% |
| 2006 Q3 | -0.03 USD | 0.0% |
| 2006 Q4 | -0.02 USD | 14.77% |
| 2006 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -0.60 USD | -205.0% |
| Ampio Pharmaceuticals, Inc. | -10.67 USD | 82.849% |
| Armata Pharmaceuticals, Inc. | -1.91 USD | 4.188% |
| Azitra, Inc. | -54.76 USD | 96.658% |
| Can-Fite BioPharma Ltd. | -1.79 USD | -2.235% |
| Chromocell Therapeutics Corporation | -1.28 USD | -42.969% |
| Calidi Biotherapeutics, Inc. | -1.73 USD | -5.78% |
| CEL-SCI Corporation | -0.73 USD | -150.685% |
| iBio, Inc. | -6.50 USD | 71.846% |
| Lineage Cell Therapeutics, Inc. | -0.12 USD | -1425.0% |
| MAIA Biotechnology, Inc. | -1.49 USD | -22.819% |
| Matinas BioPharma Holdings, Inc. | -5.28 USD | 65.341% |
| Navidea Biopharmaceuticals, Inc. | -0.59 USD | -210.169% |
| NovaBay Pharmaceuticals, Inc. | -138.65 USD | 98.68% |
| NanoViricides, Inc. | -0.70 USD | -161.429% |
| Oragenics, Inc. | -9.18 USD | 80.065% |
| BiomX Inc. | -5.10 USD | 64.118% |
| BiomX Inc. | -5.10 USD | 64.118% |
| Protalix BioTherapeutics, Inc. | 0.12 USD | 1625.0% |
| Palatin Technologies, Inc. | -2.02 USD | 9.406% |
| Scorpius Holdings, Inc. | -347.20 USD | 99.473% |